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Cytotoxic T lymphocytes (CTL) are equipped with a range of effector functions that
contribute both to the control of intracellular pathogens and dysregulated cellular
proliferation and to the development of certain immunopathologies such as
autoimmune disease. Qualitative analyses of various CTL responses have revealed
substantial heterogeneity in the diversity of functions that are mobilized in response to
antigen. Here, we studied the influence of the CD8 co-receptor, which is known to
enhance antigen recognition by CTL, on the secretion of eight different cytokines and
chemokines by human CTL clones using flow cytometric bead array. Our results show
that abrogation of MHC class I/CD8 interactions exerts a differential influence on the
distinct individual effector functions that are elicited in responseto agonist ligands. The
magnitude of this co-receptor blockade inhibitory effect was clearly related to the
hierarchy of cytokine secretion in terms of activation threshold because those functions
requiring the highest amounts of antigen were most affected. Thus, modulation of CD8
activitycaneffectivelytune notonly thesensitivitybutalsothequalitativeprofileof CTL
responses.
Introduction
Cytotoxic T lymphocytes (CTL) are key components of
the adaptive immune system, conferring protection
againstintracellular microbesandmalignanciesthrough
the recognition of specific antigenic determinants
expressed in association with major histocompatibility
complex class I (MHCI) molecules on the cell surface. In
addition to mediating the lysis of target cells by the
directed release of cytotoxic agents upon activation [1],
CTL are equipped with a range of effector functions that
participate in the communication between different
cellular components of the immune system and elicit
anti-microbial activity independently of cytolytic mech-
anisms [2–4]. These involve the release of soluble
molecules (cytokines and chemokines) that affect the
migration and cellular functions of numerous somatic
cells.
Studies examining qualitative aspects of the CTL
response have revealed that the arsenal of effector
functions mobilized by CD8
+ T cells in response to
antigen can be strikingly heterogenous [5]. Variations in
the effector function profile of T cell populations have
been linked to functional divergence between subsets of
cells at different stages of differentiation [6], factors
associated with the nature of the pathogen [7] and
characteristics of the infection such as antigen dose and
persistence [8, 9], the identity of the targeted epitope
[10], and the expression of certain co-stimulatory
molecules such as CD28 [11, 12]. It seems likely that,
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part for the inability of the immune system to contain
certain infections or tumours. For instance, it has been
proposed that the cytotoxic functions of HIV-1-specific
CTL were deficient because these cells were found to
produce lowlevelsof perforincomparedtoCMV-specific
CTL from the same donors [13, 14].
It is well accepted that the activation of different
effector functions obeys a hierarchical organization,
which is determined by the signal intensity elicited by
Tcell receptor (TCR) engagements and the level of TCR
occupancy [15, 16]. For example, it has been clearly
established that secretion of interleukin (IL)-2 by CD4
T cells requires stronger signals than those necessary to
trigger IFN-c release [17]. The activation thresholds
required for these two functional outcomes, as well as
for others, are thus quantitatively distinct. Therefore,
the commonly described disparity between functional
profiles may be explained, at least in part, by clonotypic
variability with respect to antigen sensitivity. Indeed, it
was recently proposed that the higher propensity of
murine CTL specific for the influenza A epitope D
bPA224
to elicit a diverse response, characterised by high
proportions of IL-2-secreting cells, compared to
D
bNP366-specific cells correlated with intrinsically high-
er avidities for antigen [18].
Several reports have clearly established that the CTL
co-receptor CD8 enhances the efficiency of antigen
recognition by favouring extracellular interactions
between the TCR and antigen [19, 20], and by
promoting the initiation of the signalling cascade
following TCR triggering [21, 22]. However, this effect
is not systematically required to trigger full CTL
activation since ligands with high affinity for the TCR,
such as can occur in the domain of xeno- and allo-
reactive responses, are largely independent of co-
receptor activity [23, 24]. Nonetheless, most syngeneic
interactions, which are more relevant to the normal
contextof natural immunity, havebeen showntodisplay
various degrees of “CD8 dependency” [23].
Here, we investigate the influence of the CD8 co-
receptor effect on the deployment of an array of effector
functions by activated human CTL clones. Abrogation of
co-receptor engagement using point-mutated MHCI
molecules revealed that CD8 exerts a differential
influence on the individual effector functions that are
triggered by agonist ligands. Thus, by tuning the
intensity of TCR signals, the co-receptor has a direct
influence on the functional profile of CTL and thereby
contributes to the qualitative consequences of antigen
recognition.
Results
Profile and hierarchical relationship of effector
functions in four CTL clones
The cytokine and chemokine secretion profile of four
different CTL clones, described in Table 1, were
examined in detail using multiplex flow cytometric
bead array (Fig. 1). Stimulation with high doses of
cognate antigenrevealed differences in effector function
diversity for each clone, with clones c23 and ILA1
showingtheleastdiverseprofiles(Fig.1A).Surprisingly,
in the case of SLY-10, substantial amounts of the CC
chemokine MCP-1 were released upon activation
(Fig. 1A). In addition to interclonal qualitative differ-
ences, the maximal secreted quantity of the different
cytokines and chemokines seemed to follow a random
pattern for each clone. In the example shown, clone
SLY-10 released high amounts of TNF-a compared to
MIP1-b, whereas the opposite was true in the case of
clones 003 and c23 (Fig. 1A).
The hierarchy of effector functions, established
according to the logEC50 of each read-out, was identical
for all tested HLA-A*0201-restricted CTL (Fig. 1B).
Secretion of the chemokines MIP1-b and RANTES
required the lowest amounts of antigen, whereas IL-2
release could only be detected at peptide doses that
exceeded those necessary to trigger TNF-a and IFN-c
release. These results are in agreement with previous
studies investigating the mobilisation of Tcell functions
in response to antigen [16, 17, 25]. In the case of clone
SLY-10, secretion of the chemokine MCP-1 required
doses of antigen similar to those triggering IFN-c and
TNF-a release, two cytokines that are known to have an
active role in adaptive immunity. Strikingly, the
concentrations of peptide required to activate c23 were
substantially higher than for the three HLA-A*0201-
Table 1. Description of the antigen restriction and specificity of the human CTL clones used in this study
CTL clone Origin HLA restriction Epitope
c23 HIV-1-infected patient A*6801 ITKGLGISYGR (HIV-1 Tat39–49)
SLY-10 HIV-1-infected patient A*0201 SLYNTVATL (HIV-1 Gag p1777–85)
003 HIV-1-infected patient A*0201 SLYNTVATL (HIV-1 Gag p1777–85)
ILA1 Healthy donor A*0201 ILAKFLHWL (hTERT540–548)
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antigen (KD =7 lM) is in the range of most antiviral
TCR/pMHCI interactions measured to date (Gostick et
al., unpublished data), this likely reflects either a low
intrinsic antigen sensitivity, perhaps resulting from the
impaired binding of CD8 to HLA-A*6801, or a poor
loading efficiency of the unusually long 11-mer Tat39–49
peptide onto HLA-A*6801 molecules.
The functional profile of both HIV-1 Gag p1777–85-
specific CTL clones in response to agonist ligands of
different potencies was examined in detail (Fig. 1C, D).
The 3H and 3S epitope variants have previously been
identified as weak agonists of CTL clone 003 [26, 27].
Release of the chemokines MIP1-b and RANTES, which
rank highly in the hierarchy of effector functions
(Fig. 1B), remained similar in magnitude to the levels
secreted in responsetowild-type (WT) or 'index' peptide
when clone 003 CTL were stimulated with the 3H
variant, whereas secretion of lower-order cytokines was
substantially reduced or abrogated (Fig. 1C). Stimula-
tion with the 3S peptide triggered only minimal
production of MIP1-b, RANTES and, to an even lesser
extent, IFN-c (Fig. 1C). Similarly, activation of SLY-10
with the weak agonists 3F and 3H resulted in selective
blockade of lower-order effector functions (Fig. 1D).
Co-receptor dependency is more marked for weak
agonist ligands
The release of soluble factors by the two HLA-A*0201
HIV-1 Gag p1777–85-specific clones in response to
naturally occurring variants with different agonistic
properties was assessed in detail (Fig. 2, 3). In order to
evaluate the influence of CD8 on antigen recognition,
peptides were loaded on target cells expressing either
WT or mutant HLA-A*0201 molecules (CD8-null)
Figure 1. Effector function profiles and hierarchies in four human CTL clones. (A) CTL were stimulated using Hmy.2 C1R cells
transfected with HLA-A2 WT molecules loaded with 10
–5 M of the corresponding cognate peptide. The effector function profile of
each clone was evaluated by measuring cytokine and chemokine concentrations in the culture supernatant after 4-h incubation.
NosecretionofIL-4wasobservedinthecaseofILA1andc23clones.(B)CytokineandchemokinereleasebythefourCTLcloneswas
assessed in dose-response experiments using varying concentrations of antigen to pulse HLA-A2 WT Hmy.2 C1R cells. Data were
plottedandfittedtoanon-linearsigmoidaldose-responsecurveaccordingtothefollowingequation:Y = YMIN +(Y MAX –Y MIN)/[1 +
10e (logEC50 – X)], and logEC50 values were calculated accordingly for the curves that reached a plateau. Effector functions
logEC50valuesshownforeachclonearerepresentativeofthreeindividualexperiments.(C, D)Functionalprofilesofclones 003(C)
and SLY-10 (D) in response to three different agonist peptides; HLA-A2 WT Hmy.2 C1R cells were pulsed with 10
–5 M of each
indicated peptide prior to the assay. A degree of variability in the absolute concentration values of secreted soluble factors was
observed between separate measurements. This is exemplified by the respective amounts of TNF-a and IFN-c secreted by
clone 003 in response to the index Gag p1777–85 epitope in (A, C). However, the order of secretion of the soluble factorswith respect
to peptide dose was not affected by these quantitative differences and the same hierarchy of effector functions was always
observed.
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and chemokineproduction by clone 003 CTL was measured in response to three natural variants of the HLA-A2 HIV-1-derived Gag
p1777–85epitopepresentedbyHmy.2C1RcellstransfectedwitheitherHLA-A2WTorHLA-A2CD8-null(D227K/T228A)moleculesas
indicated. Concentration of each molecule was measured simultaneously from each assay well by multiplex bead array: (A, B)
MIP1-b; (C, D) RANTES; (E, F) MIP1-a; (G, H) IFN-c; (I, J) TNF-a; (K, L) IL-2. Assays were performed in duplicate; mean values and
standard deviation from the mean are shown. Data shown are representative of three experiments.
Figure 3. Co-receptor dependency of antigen recognition by CTL clone SLY-10 in response to three different agonist peptides.
Production of soluble factors by SLY-10 CTL was measured in response to three natural variants of the HLA-A2-restricted HIV-1-
derived Gag p1777–85 epitope presented by Hmy.2 C1R cells transfected with either HLA-A2 WTor HLA-A2 CD8-null molecules as
indicated. Cytokine and chemokine concentrationswere measured simultaneously from each assay well by multiplex bead array:
(A, B) MIP1-b; (C, D) RANTES; (E, F) MIP1-a; (G, H) IFN-c; (I, J) TNF-a; (K, L) IL-2. Assays were performed in duplicate; mean values
and standard deviation from the mean are shown. Data shown are representative of three experiments.
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(D227K/T228A) of the heavy chain that abrogates
binding to CD8 without affecting TCR binding [21].
For both CTL clones, recognition efficiency of the
strongest 'index' ligand SLYNTVATL was minimally
affected by the loss of the extracellular CD8 interaction
with MHCI (Fig. 2, 3). In contrast, as a general
observation, the recognition of weaker agonists (3H,
3F or 3S peptide variants) characterised by lower
recognition efficiencies in dose-response experiments
was either dramatically reduced or completely abro-
gated in the absence of MHCI/CD8 interactions. In the
case of the 3H peptide, presentation by cells bearing
CD8-null HLA-A*0201 molecules did not trigger any
response even at high antigen doses for both CTL clones
tested, with the exception of MIP1-b and, to a lesser
extent, RANTES release (Fig. 2A–D; 3A–D). Similar
observations held true for recognition of the 3F peptide
by SLY-10 for which MIP1-b, RANTES and MIP1-a
release were reduced by the CD8-null mutation
(Fig. 3A–F), whereas no IFN-c, TNF-a or IL-2 were
produced in the obsence of MHCI/CD8 interaction
(Fig. 3G–L). Thus, these results indicate that CD8
dependency is inversely correlated with the potency of
the agonist ligand, a notion consistent with data
reported in other studies [23].
Correlation between effector function hierarchy
and susceptibility to co-receptor blockade
Two observations can be made from the dose-response
secretion patterns obtained from CTL clones 003 and
SLY-10. First, all functional outcomes resulting from
antigen exposure are not equally affected by disruption
of the MHCI/CD8 interaction. This is exemplified in the
case ofclone 003stimulatedwiththe3Hpeptidevariant
bycomparing the pattern of MIP1-b release (Fig. 2A, B),
which was only reduced to a small extent in the case of
the CD8-null targets, with those for MIP1-a, IFN-c and
TNF-a (Fig. 2E–J), in which cases MHCI/CD8 disruption
abrogated secretion. Similar observations were made in
the case of clones 003 and SLY-10 stimulated with all
tested HIV-1 Gag p1777–85 peptide variants (Fig. 2, 3).
Second, the main factor governing this differential
co-receptor dependency appears to be the hierarchy of
effector functions. Of all tested effector functions,
MIP1-b secretion was consistently the least CD8-
dependent in addition to being the function triggered
at the lowest level of antigen (Fig. 1B; 2A; 3A). IL-2
secretion, in contrast, occupies the opposite end of the
functional spectrum, requiring the highest amounts of
antigen (Fig. 1B; 2K; 3K). Accordingly, for most agonist
ligands tested, faithful MHCI/CD8 interactions were
required to trigger efficient IL-2 release. The secretion
profiles of IFN-c and MIP1-a oscillated between low and
total CD8 co-receptor dependency, according to the
recognition efficiencycharacteristics of the ligand under
consideration. Altogether these results point to a crucial
role for both antigen potency and effector function
hierarchy in determining the degree of co-receptor
dependency of antigenic stimulation.
Atypical secretion of the chemokine MCP-1 and
co-receptor dependency
Secretion of the CC chemokine MCP-1 by CTL clone
SLY-10 appeared to be an intriguing feature since, to the
best of our knowledge, secretion of this molecule by
Tcells has not been documented previously. Initial dose-
response experiments revealed that the secretion profile
of MCP-1 had a logEC50 nearly identical to those for
TNF-a and IFN-c (Fig.1B). In agreement with the notion
that the hierarchical organization of CTL effector
functions is an important factor that determines the
influence of co-receptor interactions on CTL activation,
MCP-1 release showed a pattern of CD8 dependency
similar to that of TNF-a and IFN-c (Fig. 3G–J; Fig. 4).
Thus, it seems that secretion of MCP-1 by SLY-10 both
requires relatively high amounts of antigen and displays
a degree of co-receptor dependency similar to that of
two cytokines known to exert antiviral functions in vivo.
Discussion
The range of effector functions deployed by CTL in
response to antigen in vivo is known to exhibit a degree
of variability. Several factors, including intrinsic cellular
properties related to differentiation status and inter-
clonal functional differences, have been shown to have
an impact on qualitative aspects of the CTL response.
Secretion of the chemokine MCP-1 (CCL2) by one of the
CTL clones used in our study illustrates this type of
Figure 4. Dose-response profile and co-receptor dependency of
MCP-1 secretion by CTL clone SLY-10. MCP-1 levels in the
supernatant of assay wells containing CTL mixed with APC
expressing HLA-A2 WT (A) or HLA-A2 CD8-null (B) molecules
were determined from the same assay well shown in Fig. 3.
Meanvaluesandstandard deviationfromthemeanare shown.
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described for a variety of cell types including dendritic
cells, endothelial cells, fibroblasts and macrophages
[28]. This chemokine is involved in promoting the
recruitment of monocytes to infection sites and has also
been proposed to play a role in CD4 T cell Th1/Th2
polarization [29] by negatively regulating the Th1
response [30]. Secretion of MCP-1 was shown to be
induced by different sorts of stimuli including the action
of several cytokines such as IFN-c, IL-1, IL-4 and TNF-a
[31, 32] as well as vascular endothelial stress [33].
Important up-regulation of MCP-1 serum levels was
notably shown to occur in atherosclerotic lesions [34].
Our results suggest that antigenic activation of CTL may
be another source of MCP-1 in vivo. By extrapolation of
theresults obtainedwithclone SLY-10,MCP-1is likelyto
be triggered by levels of antigen characteristic of in vivo
viral infection settings since its position within the
functional hierarchy was similar to that of IFN-c and
TNF-a. It is possible that the secretion of MCP-1 by our
CTL clone is the exception rather than the rule and
further work will be required in order to establish
whether this observation is of general relevance.
Antigen load [35] and the nature of antigenic
stimulation [8] have also been proposed to affect the
quality of T cell responses. It is well established that
stimulation with suboptimal altered peptide ligands can
induce only some of the effector functions in the T cell
armamentarium. Weak agonist ligands only elicit those
functions that normally require low doses of strong
agonists while a more intriguing category of antigens,
the so-called partial agonists, selectively elicit a set of
functional outcomes irrespective of the established
functional hierarchy [36, 37]. In our system, the peptide
variants we studied all belonged to the former category
since suboptimal antigens triggeredonlythe secretion of
effector functions at the top of the functional hierarchy.
Thus, the correlation between ligand potency, response
diversity and functional hierarchy remained apparent in
all cases; for peptides of intermediate potency, only
secretion of IL-2 was lost, whereas activation with lower
potency agonists resulted in the additional abrogation of
IFN-c,TNF-aandMIP1-a(aswellasMCP-1inthecaseof
SLY-10).
Our data reveal that the lower-order CTL effector
functions, i.e. those requiring high amounts of antigen,
are disproportionately affected by co-receptor blockade.
Indeed, there appears to be an absolute antigen
sensitivity threshold below which disruption of CD8
binding dramatically impairs the recruitment of any
effector function, regardless of the potency of the
agonist ligand considered. Specifically, in the context of
the two HIV-1 Gag p17-specific CTL clones 003 and
SLY-10, effector functions for which half-maximal
responses were elicited at peptide concentrations above
10
–7–10
–6 M showed a high degree of co-receptor
dependency (Fig. 5). Consequently, the main difference
between a strong and a weak agonist was the number of
functions impaired by abrogation of co-receptor bind-
ing. For instance, only the secretion of lower-order
factors such as IL-2 was substantially affected in the case
of stimulationwithpotentantigenswhile most,ifnotall,
Figure 5. The dependency on CD8 co-receptor activity for the efficient secretion of each effector function varies as an inverse
function of antigen sensitivity. Each cytokine is colour-coded as indicated and ranked on the x axis according to the peptide
concentration (M) required to trigger half-maximum release (logEC50) in response to a particular ligand (represented by different
geometrical figures): 3Yand 3H for clone 003 (A), and 3Y, 3F and 3H for clone SLY-10 (B). Only those functions for which the dose-
response profile levelled off, yielding reliable EC50 values by curve fitting, were taken into account to plot this graph. Functions
with low EC50 values (<10
–8 M) were excluded for clarity. “Co-receptor dependency” for each read-out is represented as the ratio
between maximal cytokine or chemokine concentration (RMAX) measured for each ligand presented in the context of WT HLA-A2
and CD8-null (KA) HLA-A2 molecules. High RMAXWT/RMAXKA values are thus indicative of a high degree of CD8 dependency. In
contrast, effector functions for which the co-receptor interaction has little effect have RMAXWT/RMAXKA ratio values close to 1.
RMAXWT/RMAXKA ratios for functional read-outs with EC50 values below 10
–8 M were close to 1 (data not shown). The ratio
between maximum responses triggered by WT and CD8-null HLA-A2 molecules increases exponentially for logEC50 values
>10
–7–10
–6 M. Data were fitted to the equation Y = 1  exp(K  X); K = 1.4510
6 (A); K = 0.3810
6 (B).
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agonists relied on faithful MHCI/CD8 interactions even
at high antigen density.
The different co-receptor activities of CD8 are known
to synergize to enhance proximal signalling events [21,
38], which are crucial for increasing the sensitivity of
antigen recognition. Our results indicate that co-
receptor-mediated tuning of the signalling pathways
downstream of TCR engagement not only improves the
dose-response pattern of CTL activation but also
partially determines the diversity of effector functions
mobilised at a given dose of antigen. As a consequence,
we predict that the cytokine profile of a CTL response is
substantially influenced by co-receptor engagement for
the natural antigen densities present on the surface of
virally infected cells. This issue becomes particularly
salient in the case of suboptimal weak agonist ligands
such as the natural HIV-1 altered peptide ligands used
here. The effect of the co-receptor on the quality of the
CTL response reported here is also likely to be an
important determinant in the context of tumor-specific
and autoimmune CTL responses. The TCR/pMHCI
affinities of these types of interactions are believed to
occupy the lower reaches of the functionally relevant
TCR/pMHCI affinity spectrum, a situation in which the
contribution of CD8 to CTL activation is known to be
crucial [23].
Recent investigations of CTL functional profiles in
mice and humans have lead to the suggestion that the
functional diversity of CTL responses provides an
indication of immune antiviral control and clinical
outcome [35]. Specifically, the CTL responses to viral
epitopes measured ex vivo from vaccinated individuals
were shown to be more diverse than in the context of
natural immunization [7]. Moreover, it has recently
been established in the context of HIV-1 infection that
the proportion of CTL exhibiting a polyfunctional
response to multiple epitopes was substantially higher
in long-termnonprogressors than in infectedindividuals
with a less favourable clinical course [39]. The authors
of this report proposed that the functional diversity of
theCTLresponse,rather thanitsmagnitude,providesan
indication of antiviral protection in HIV-1-infected
patients; this might also hold true in the context of
other viral infections. Interestingly, the two cytokines
consistently present at a higher frequency in antigen-
specific CTL from long-term nonprogressors were the
lower-order effector functions TNF-a and IL-2.
Recent reports have suggested a possible regulatory
role for CD8 with respect to the responsiveness and
sensitivity of CTL mediated by down-regulation of
expression [40, 41], modifications of TCR-CD8 coloca-
lization [42] and post-translational modulation of CD8
activity at different developmental stages [43, 44]. Our
resultsindicatethatifsuchregulatoryactivityisindeeda
means tomodulatethe state of CTL responsiveness,then
interference with CD8 co-receptor activity is also likely
to tune qualitative aspects of the response to antigen by
disproportionately affecting lower-order effector func-
tions. Whether this phenomenon has functional im-
plicationsinvivoisdifficulttoassess,butitistemptingto
speculate that down-regulation of CD8 co-receptor
activity, such as appears to occur following antigenic
stimulation of effector T cells in particular [41, 45],
might serve as a regulatory feedback mechanism that
tames the CTL response in a relevant spatio-temporal
context. According to our data, one consequence of such
a mechanism would be the selective inhibition of lower-
order CTL functions (IFN-c, TNF-a and IL-2 especially)
upon antigen re-exposure in the short term without
major effects on higher-order effector mechanisms such
as cytolysis and the release of MIP1-b and RANTES. It is
interesting to note that release of the cytokines IFN-c
and TNF-a, which have been implicated as causal agents
in septic shock [46], is highly dependent on CD8. Even
though many other immune cells, including effectors of
innate immunity, are major sources of these molecules,
it has been shown that inadequate cytokine release by
CTL was sufficient to induce severe consequences
following viral infections [47]. Tight regulation of the
stimulatory mechanisms inducing cytokine and chemo-
kine release is therefore required in order to keep the
immune response under control.
A recent study investigating the role of CD8 in the
activation of CTL by soluble tetrameric pMHCI com-
plexes suggested that, in contrast to naive cells, cytokine
release by memory CTL did not require co-receptor
interactions whereas calcium mobilization and prolif-
eration were CD8-dependent for both naive effector and
memory cells [48]. This is in agreement with the notion
that elicitation of some effector functions differentially
requires co-receptor interactions. The cells we used in
this study were CTL clones established after several
rounds of in vitro stimulation and it is not clear to what
extent the memory phenotype of these cells is mean-
ingful. Yet, these CTL are clearly antigen-experienced
and exhibit differential degrees of co-receptor depen-
dency for the release of cytokines. The apparent minor
discrepancy between our results and those of Kerry and
colleagues [48] with regard to the CD8 dependency of
cytokine release may lie in the fact that we used cell
surfacepresentationforantigen-specificstimulationand
that, in our study, differences in the release of effector
molecules were most obvious at low cell surface antigen
densities, a situation very different from activation with
soluble multimeric antigens.
Finally, it was reported that blocking the interaction
between CD4 and MHC class II molecules differentially
affected the secretion of IL-2 versus IL-3 cytokines by
CD4
+ T cells [49]. This suggests that regulation of the
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activities may be a general feature of T cells and that
a raison d'Þtre of the dual TCR/co-receptor antigenic
ligand recognition system may be to regulate the T cell
response at the level of the incoming stimulus through
differential modulation of co-receptor activity. This
phenomenon could potentially contribute to the estab-
lishment of T cell tolerance in the periphery. Further-
more, from a practical perspective, the effect of CD8 on
CTL activation could potentially be exploited therapeu-
tically to down-modulate deleterious CTL responses.
Materials and methods
Cytokine and chemokine bead arrays
Approximately10 000 APCwerepre-pulsedwiththe indicated
concentrations of peptide and washed twice with serum-free
RPMI 1640 medium (Sigma) supplemented with 2 mM
glutamine (Gibco), 100 U/mL penicillin (Gibco) and 100 U/
mL streptomycin (Gibco) (RPMI-PSG medium). CTL (15 000
or30 000)wereaddedineachassaywellandincubatedfor4 h
at 37
C in 96-well plates. Cells were pelletedbycentrifugation;
supernatants were harvested and assayed with the human
Th1/Th2 Cytokine and Chemokine kits (BD Pharmingen)
according to the manufacturer's instructions. Analysis was
performed with a FACSCalibur (Becton Dickinson) flow
cytometer.
B cell lines
EBV-immortalized Hmy2.C1R cells expressing WT HLA-
A*0201 or CD8-null (D227K/T228A) HLA-A2 molecules are
described elsewhere [21]. These cells were maintained in
RPMI-PSG medium supplemented with 10% heat-inactivated
fetal calf serum (Globepharm) (R10 medium). Medium was
replaced every 2 days to keep the cells in a state of constant
growth.
Generation of CTL clones
Peripheral blood mononuclear cells isolated from HLA-A*0201
positive healthy donors or patients were stimulated with
antigenbyautologouspresentation of peptide diluted at a final
concentration of 10
–6 or 10
–7 M. Cells were maintained in R10
medium to which IL-2 (Peprotech) was gradually added from
day 3 post-stimulation up to a maximum concentration of
100 U/mL. Following successful expansion of antigen-specific
cells, CTL clones were isolated by limiting dilution in a 96-well
plate at an average of 0.3 cells per well containing R10
supplemented with 100 U/mL IL-2 (Peprotech), 10% T-stim
(Becton Dickinson) and mixed irradiated allogeneic feeder
cells from at least three unrelated donors stimulated with
phytohemagglutinin. The antigen specificity of growing cells
was tested by pMHCI multimer staining and IFN-c ELISPOT
assays.
Peptides
The hTERT540–548 (ILAKFLHWL) peptide was purchased from
Pepscan (Lelystad, The Netherlands). The HIV-1 Tat39–49 HLA-
A*6801-restricted peptide (ITKGLGISYGR) together with the
HIV-1 Gag p1777–85 index peptide (SLYNTVATL) and mono-
substituted variants thereof were purchased from Invitrogen.
Peptide preparations used in this study were purified by mass
spectrometry and were >95% pure. Powder was initially
dissolved in DMSO and further diluted in serum-free RPMI-
PSG to the desired concentrations.
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